Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/1955-0a51

technical paper

ENDO 2022

July 11, 2022

Atlanta, United States

Evolution of Thyroid Eye Disease (TED) Treatment withTEPEZZA (teprotumumab-trbw): Translating Bench to Bedside

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2022

TSH-R-Antibody Assay Comparison: A US Based, Prospective, Multicenter, Blind Study
technical paper

TSH-R-Antibody Assay Comparison: A US Based, Prospective, Multicenter, Blind Study

ENDO 2022

George Kahaly

11 July 2022

Similar lecture

Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia
technical paper

Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

ENDO 2022

Ron Newfield

11 July 2022

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved